<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1962774-B1" country="EP" doc-number="1962774" kind="B1" date="20140101" family-id="38006451" file-reference-id="303784" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146553533" ucid="EP-1962774-B1"><document-id><country>EP</country><doc-number>1962774</doc-number><kind>B1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-06836675-A" is-representative="NO"><document-id mxw-id="PAPP154827456" load-source="docdb" format="epo"><country>EP</country><doc-number>06836675</doc-number><kind>A</kind><date>20061031</date><lang>EN</lang></document-id><document-id mxw-id="PAPP205136102" load-source="docdb" format="original"><country>EP</country><doc-number>06836675.6</doc-number><date>20061031</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140445745" ucid="US-2006042381-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2006042381</doc-number><kind>W</kind><date>20061031</date></document-id></priority-claim><priority-claim mxw-id="PPC140451725" ucid="US-73187505-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>73187505</doc-number><kind>P</kind><date>20051101</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130821</date></intention-to-grant-date><search-report-dispatch-date><date>20110210</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988097654" load-source="docdb">A61Q  11/00        20060101ALI20130104BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988107444" load-source="docdb">A61K   8/19        20060101AFI20130104BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988125611" load-source="docdb">A61K  33/24        20060101ALI20130104BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1651145514" load-source="docdb" scheme="CPC">Y02A  50/483       20180101 LA20180409BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1651145515" load-source="docdb" scheme="CPC">Y02A  50/473       20180101 LA20180409BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1742351619" load-source="docdb" scheme="CPC">A23K  20/20        20160502 LI20171026BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1913206894" load-source="docdb" scheme="CPC">A23L  33/16        20160801 LI20160801BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1944071012" load-source="docdb" scheme="CPC">A61Q  11/00        20130101 LI20160430BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1944072619" load-source="docdb" scheme="CPC">A01N  59/16        20130101 LI20160430BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1944075689" load-source="docdb" scheme="CPC">A61K  31/28        20130101 LI20160428BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1944077213" load-source="docdb" scheme="CPC">A61K   8/19        20130101 LI20160430BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1944084371" load-source="docdb" scheme="CPC">A61K  33/24        20130101 FI20160428BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988098668" load-source="docdb" scheme="CPC">A61L2300/102       20130101 LA20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988104195" load-source="docdb" scheme="CPC">A23V2002/00        20130101 LA20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988105327" load-source="docdb" scheme="CPC">A23L   3/358       20130101 LI20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988110818" load-source="docdb" scheme="CPC">A61K   8/365       20130101 LI20131119BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988114312" load-source="docdb" scheme="CPC">A61L  12/088       20130101 LI20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988115531" load-source="docdb" scheme="CPC">A61L  15/46        20130101 LI20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988120590" load-source="docdb" scheme="CPC">A61Q  11/02        20130101 LI20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988123280" load-source="docdb" scheme="CPC">A61K   8/24        20130101 LI20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988125313" load-source="docdb" scheme="CPC">A61L2300/404       20130101 LA20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988128411" load-source="docdb" scheme="CPC">A61K2800/58        20130101 LA20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988133695" load-source="docdb" scheme="CPC">A61L   2/16        20130101 LI20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988137057" load-source="docdb" scheme="CPC">A61L   2/18        20130101 LI20131123BHEP        </classification-cpc><classification-cpc mxw-id="PCL2094196138" load-source="docdb" scheme="CPC">A01N  55/02        20130101 LI20140710BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132193083" lang="DE" load-source="patent-office">KONTROLLE DES WACHSTUMS VON ORALEN UND OBERFLÄCHLICHEN MIKROORGANISMEN MIT GALLIUM-VERBINDUNGEN</invention-title><invention-title mxw-id="PT132193084" lang="EN" load-source="patent-office">GROWTH CONTROL OF ORAL AND SUPERFICIAL MICROORGANISMS USING GALLIUM COMPOUNDS</invention-title><invention-title mxw-id="PT132193085" lang="FR" load-source="patent-office">CONTROLE DE LA CROISSANCE DE MICRO-ORGANISMES ORAUX ET SUPERFICIELS A L'AIDE DE COMPOSES AU GALLIUM</invention-title><citations><non-patent-citations><nplcit><text>STOJILJKOVIC I ET AL: "Non-iron metalloporphyrins: potent antibacterial compounds that exploit haem/Hb uptake systems of pathogenic bacteria", MOLECULAR MICROBIOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 31, no. 2, 1 January 1999 (1999-01-01), pages 429 - 442, XP002571540, ISSN: 0950-382X, [retrieved on 20020530], DOI: 10.1046/J.1365-2958.1999.01175.X</text><sources><source mxw-id="PNPL62931726" load-source="docdb" name="EXA"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division-into"><child-doc ucid="EP-13190163.9"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13190163.9</doc-number><date>20131024</date></document-id></child-doc><parent-doc ucid="EP-06836675-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>06836675</doc-number><kind>A</kind><date>20061031</date></document-id><parent-grant-document ucid="EP-1962774-B1"><document-id><country>EP</country><doc-number>1962774</doc-number><kind>B1</kind><date>20140101</date></document-id></parent-grant-document></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR918158887" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SINAI SCHOOL MEDICINE</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918150283" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>MOUNT SINAI SCHOOL OF MEDICINE</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918171099" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>PERL DANIEL P</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918170611" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>PERL, DANIEL, P.</last-name></addressbook></inventor><inventor mxw-id="PPAR918997125" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>PERL, DANIEL, P.</last-name><address><street>c/o Sideromics, LLC 7710 Woodmont Avenue Apartment 1205</street><city>Bethesda, MD 20814</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918155002" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>MOALEM SHARON</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918136173" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>MOALEM, SHARON</last-name></addressbook></inventor><inventor mxw-id="PPAR918997124" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>MOALEM, SHARON</last-name><address><street>c/o Sideromics, LLC 7710 Woodmont Avenue Apartment 1205</street><city>Bethesda, MD 20814</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR918997127" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Mount Sinai School of Medicine</last-name><iid>101231755</iid><address><street>One Gustave L. Levy Place</street><city>New York, New York 10029</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR918997126" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Vossius &amp; Partner</last-name><iid>100751388</iid><address><street>Siebertstrasse 4</street><city>81675 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2006042381-W"><document-id><country>US</country><doc-number>2006042381</doc-number><kind>W</kind><date>20061031</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2007053581-A2"><document-id><country>WO</country><doc-number>2007053581</doc-number><kind>A2</kind><date>20070510</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548978039" load-source="docdb">AT</country><country mxw-id="DS548829056" load-source="docdb">BE</country><country mxw-id="DS548987834" load-source="docdb">BG</country><country mxw-id="DS548884098" load-source="docdb">CH</country><country mxw-id="DS548829057" load-source="docdb">CY</country><country mxw-id="DS548976242" load-source="docdb">CZ</country><country mxw-id="DS548973475" load-source="docdb">DE</country><country mxw-id="DS548829058" load-source="docdb">DK</country><country mxw-id="DS548829059" load-source="docdb">EE</country><country mxw-id="DS548978537" load-source="docdb">ES</country><country mxw-id="DS548987835" load-source="docdb">FI</country><country mxw-id="DS548987836" load-source="docdb">FR</country><country mxw-id="DS548973476" load-source="docdb">GB</country><country mxw-id="DS548829060" load-source="docdb">GR</country><country mxw-id="DS548976243" load-source="docdb">HU</country><country mxw-id="DS548884099" load-source="docdb">IE</country><country mxw-id="DS548829061" load-source="docdb">IS</country><country mxw-id="DS548987837" load-source="docdb">IT</country><country mxw-id="DS548829062" load-source="docdb">LI</country><country mxw-id="DS548973477" load-source="docdb">LT</country><country mxw-id="DS548978040" load-source="docdb">LU</country><country mxw-id="DS548987838" load-source="docdb">LV</country><country mxw-id="DS548973478" load-source="docdb">MC</country><country mxw-id="DS548978538" load-source="docdb">NL</country><country mxw-id="DS548978539" load-source="docdb">PL</country><country mxw-id="DS548987839" load-source="docdb">PT</country><country mxw-id="DS548976244" load-source="docdb">RO</country><country mxw-id="DS548978540" load-source="docdb">SE</country><country mxw-id="DS548884100" load-source="docdb">SI</country><country mxw-id="DS548863391" load-source="docdb">SK</country><country mxw-id="DS548978041" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63957257" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">1. INTRODUCTION</heading><p id="p0001" num="0001">The present invention relates to methods of controlling growth of microorganisms, in particular, oral and superficial bacteria and fungi that cause disorders or diseases in host organisms, by applying gallium compounds to an affected or intended area topically or superficially. The invention further relates to formulations comprising gallium compounds for controlling growth of such microorganisms and objects or materials coated therewith or incorporating same. In addition, the invention relates to animal feeds containing gallium compounds.</p><heading id="h0002">2. BACKGROUND OF THE INVENTION</heading><p id="p0002" num="0002">Gallium is a group IIIa semi-metallic element that has been used for many years for diagnosing neoplasms and inflammation in the field of nuclear medicine. Gallium has also shown some efficacy in the treatment of cancers (<nplcit id="ncit0001" npl-type="s"><text>Adamson et al., 1975, Cancer Chemothe. Rept 59:599-610</text></nplcit>; <nplcit id="ncit0002" npl-type="s"><text>Foster et al., 1986, Cancer Treat Rep 70:1311-1319</text></nplcit>; <nplcit id="ncit0003" npl-type="s"><text>Chitambar et al., 1997, Am J Clin Oncol 20:173-178</text></nplcit>), symptomatic cancer-related hypercalcemia (<nplcit id="ncit0004" npl-type="b"><text>Warrell et al., 1989, in "Gallium in the treatment of hypercalcemia and bone metastasis", Important Advances in Oncology, pp. 205-220, J.B. Lippincott, Philadelphia</text></nplcit>; <nplcit id="ncit0005" npl-type="s"><text>Bockman et al. 1994, Semin Arthritis Rheum 23:268-269</text></nplcit>), bone resorption (<nplcit id="ncit0006" npl-type="s"><text>Warrell et al., 1984, J Clin Invest 73:1487-1490</text></nplcit>; Warrell <i>et al.,</i> 1989, supra), autoimmune diseases and allograft rejection (<nplcit id="ncit0007" npl-type="s"><text>Matkovic et al., 1991, Curr Ther Res 50:255-267</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>Whitacre et al., 1992, J Newuro immunol 39:175-182</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>Orosz C.G. et al., 1996, Transplantation 61:783-791</text></nplcit>; <nplcit id="ncit0010" npl-type="s"><text>Lobanoff M.C. et al., 1997, Exp Eye Res 65:797-801</text></nplcit>), stimulating wound healing and tissue repair (<patcit id="pcit0001" dnum="US5556645A"><text>Bockman et al., U.S. Patent No. 5,556,645</text></patcit>; <patcit id="pcit0002" dnum="US6287606B"><text>Bockman et al., U.S. Patent No. 6,287,606</text></patcit>) and certain infections, such as syphilis (<nplcit id="ncit0011" npl-type="s"><text>Levaditi C. et al., 1931, C R Hebd Seances Acad Sci Ser D Sci Nat 192:1142-1143</text></nplcit>), intracellular bacterial infections, such as tuberculosis, histoplasmosis, and<!-- EPO <DP n="2"> --> leishmaniasis (<nplcit id="ncit0012" npl-type="s"><text>Olakanmi et al., 1997, J. Invest. Med. 45:234A</text></nplcit>; <patcit id="pcit0003" dnum="US6203822B"><text>Schlesinger et al., U.S. Patent No. 6,203,822</text></patcit>; <patcit id="pcit0004" dnum="WO03053347A"><text>Bernstein, et al., International Patent Application Publication No. WO 03/053347</text></patcit>), <i>Pseudomonas aeruginosa</i> infection (<patcit id="pcit0005" dnum="US6203822B"><text>Schlesinger et al., U.S. Patent No. 6,203,822</text></patcit>), and trypanosomiasis (Levaditi C. <i>et al. supra</i>).</p><p id="p0003" num="0003">Although the exact mechanism of gallium's activity against bone resorption and hypercarcemia is not well known, its antiproliferative properties against cancer cells and antimicrobial activities are said to be likely due to its competition with ferric iron (<i>i.e</i>., Fe<sup>3+</sup>) for uptake by cancer cells or microorganisms (<nplcit id="ncit0013" npl-type="s"><text>Bernstein, 1998, Pharmacol Reviews 50(4):665-682</text></nplcit>). Iron is an essential element for most living organisms, including many pathogens, and is required for DNA synthesis and various oxidation-reduction reactions (<nplcit id="ncit0014" npl-type="s"><text>Byers et al., 1998, Metal Ions Bio syst 35:37-66</text></nplcit>; <nplcit id="ncit0015" npl-type="s"><text>Guerinot et al., 1994, Annu Rev Microbiol 48:743-772</text></nplcit>; <nplcit id="ncit0016" npl-type="s"><text>Howard, 1999, Clin Micobiol Reviews 12(3):394-404</text></nplcit>). Ga<sup>3+</sup> is known to have solution- and coordination-chemistries similar to those of Fe<sup>3+</sup> (<nplcit id="ncit0017" npl-type="s"><text>Shannon, 1976, Acta Crystallographica A32:751-767</text></nplcit>; <nplcit id="ncit0018" npl-type="b"><text>Huheey et al., 1993, In Inorganic Chemistry: Principles of Structure and ReactivityI, ed. 4, Harper Collins, NY</text></nplcit>; <nplcit id="ncit0019" npl-type="s"><text>Hancock et al.,1980, In Org Chem 19:2709-2714</text></nplcit>) and behaves very similarly to Fe<sup>3+</sup> <i>in vivo</i> by binding to the iron-transport protein transferrin (<nplcit id="ncit0020" npl-type="s"><text>Clausen et al., 1974, Cancer Res 34:1931-1937</text></nplcit>; <nplcit id="ncit0021" npl-type="s"><text>Vallabhajosula et al., 1980, J Nucl Med 21:650-656</text></nplcit>). It is speculated that gallium enters microorganisms via their iron transport mechanisms and interferes with their DNA and protein synthesis.</p><p id="p0004" num="0004"><patcit id="pcit0006" dnum="US6203822B"><text>U.S. Patent No. 6,203,822</text></patcit> and International Patent Application No. <patcit id="pcit0007" dnum="WO03053347A"><text>WO 03/053347</text></patcit> disclose methods for treating patients infected with intracellular bacteria, in particular, species of the genus <i>Mycobacterium,</i> by intravenously or orally administering gallium compounds to patients infected by this class of bacteria <i>(also see</i> <nplcit id="ncit0022" npl-type="s"><text>Olakanmi et al., 2000, Infection and Immunity 68(10):5619-5627</text></nplcit>). These organisms primarily infect macrophages, which are known to store large amounts of iron and overexpress transferrin receptors. Parenterally or orally administered gallium compounds are easily taken up by the macrophages through transferrin receptors<!-- EPO <DP n="3"> --> and then, within the cells, are taken up by the infecting organisms, thereby interfering with the organisms metabolism. The antimicrobial activities of gallium against microorganisms other than intracellular organisms have thus far not been explored to a great extent.<!-- EPO <DP n="4"> --></p><p id="p0005" num="0005"><patcit id="pcit0008" dnum="GB654472A"><text>GB 654472 A</text></patcit> discloses a preparation for use in contact with the teeth made by mixing a Group III element such as yttrium, cerium, gallium, indium, lanthanum, "diolymium" or samarium, with a flavouring material, a cleaning agent and other compatible ingredient or ingredients, and/or an least slightly water-soluble salt containing fluorine.<br/>
In Example 2 a liquid dentifrice containing 1.0 gram of gallium nitrate and in Exmaple 4 a preparation for topical administration containing 2.0 grams of gallium nitrate is disclosed. These preparations are set forth in <patcit id="pcit0009" dnum="GB654472A"><text>GB 654472 A</text></patcit> to render the enamel of the teeth very resistant toward solubility in organic acids which develop in the oral cavity.</p><p id="p0006" num="0006"><patcit id="pcit0010" dnum="WO9830102A"><text>WO 98/30102</text></patcit> discloses novel non-iron metalloporphyrins, and antibacterial compositions comprising artificial metalloporphyrins (such as protoporphyrin IX) completed with a metal ion selected from metal ions including, but not limited to, gaolinium, ruthenium, copper, gallium, indium and manganese, and methods for inhibiting or killing bacteria and other microorganisms and for treating infections caused by microorganisms using the artificial metalloporphyrin.<br/>
Further disclosed are antibacterial pharmaceutical compositions comprising one or more of the non-iron metalloporphyrins incorporated in a dental rinse for application to the buccal area for the treatment or prevention of gingivitis.</p><p id="p0007" num="0007">This invention is based upon the inventors' use of gallium compounds selected from the group consisting of gallium nitrate, gallium maltolate, gallium citrate, gallium phosphate, gallium chloride, gallium fluoride, gallium carbonate, gallium formate, gallium acetate, gallium sulfate, gallium tartrate, gallium oxalate, and gallium oxide to<!-- EPO <DP n="5"> --> control the growth of pathogenic microorganisms at specific sites, such as oral cavity nasal cavities, eyes, skins and vagina, in host organisms of such pathogens as well as on the surfaces of various objects that need to be kept free of such pathogens. Such a control is accomplished through the application of gallium compounds to an affected or intended area topically, or superficially.</p><p id="p0008" num="0008">Accordingly, the present invention provides methods for controlling the growth of iron-dependent pathogenic microorganisms, comprising applying the above specified gallium compounds to an affected or intended area topically, or superficially. In one aspect; the present invention provides methods for controlling growth of iron-dependent pathogenic microorganisms, such as bacteria and fungi, at specific sites in host organisms, preferably mammals, and most preferably humans, inflicted with such pathogens, by topically or locally applying the above specified gallium compounds to said sites. Those microorganisms include, but are not limited to, bacteria within the genera <i>Streptococcus, Staphylococcus, Yersinia, Salmonella, Chlamydia, Coxilla, Ehrlichia, Francisella, Legionella, Pasteurella, Brucella, Proteus, Hilicobacter, Klebsiella, Enterobacter, Escherichia, Tropheryma, Acinetobacter, Aeromonas, Alcaligenes, Campylobacter, Capnocytophaga, Bacillus, Clostridium, Corynebacterium, Erysipelothrix, Listeria, Mycobacterium, Pseudomonas,</i> and the like; and fungi, such as <i>Candida albicans, Microsporum canis, Sporothrix schenckii, Trichophyton rubrum, Trichophyton mentagrophytes, Malassezia furfur, Pityriasis versicolor, Exophiala werneckii, Trichosporon beigelii, Coccidioides immitis, Histoplama capsulatum, Blastomyces dermatitidis, Aspergillus<!-- EPO <DP n="6"> --> fumigatus, Epidermophyton spp., Fusarium spp., Zygomyces spp., Rhizopus spp. Mucor spp.,</i> and so forth.</p><p id="p0009" num="0009">In a preferred embodiment, the microorganisms targeted by the present invention include, but are not limited to, those commonly found in the oral cavity, especially those bacteria which cause dental caries, plaques, periodontal diseases, halitosis, gingivitis and other oral diseases and disorders. Examples of such microorganisms include, but not by way of limitation, <i>Streptococcus mutans, Streptococcus sanguis, Streptococcus gordonii, Atopobium parvulum, Porphyromonas gingivalis, Eubacterium sulci,</i> and so forth. Further disclosed herein are pathogenic organisms causing infections in nasal and vaginal cavities, as well as on the skin surfaces and include <i>Staphylococcus aureus, Streptococcus pneumoniae,</i> β-hemolytic streptococci, <i>Corynebacterium minutissimum, Candida albicans, Microsporum audouinii, Microsporum canis, Microsporum gypseum, Microsporum canis, Sporothrix schenckii, Trichophyton rubrum, Trichophyton mentagrophytes, Pityriasis versicolor, Exophiala werneckii, Trichosporon beigelii, Malassezia furfur, Fusarium spp., Aspergillus spp.,</i> and the like.</p><p id="p0010" num="0010">Accordingly, one aspect of the present invention provides methods for treating or preventing diseases or disorders caused by oral bacteria or fungi in a subject, comprising applying the above specified gallium compounds to the oral cavity. In a specific embodiment, the disease or disorder includes dental caries, gingivitis, halitosis, oral thrush and the like. Further disclosed herein are methods for treating or preventing a superficial infection in a subject, comprising topically applying gallium compounds to the affected area. In a specific aspect, the superficial infection includes skin infections, vaginal yeast infections, ocular infections, and the like.</p><p id="p0011" num="0011">Further disclosed herein are methods for controlling the growth of iron-dependent pathogenic microorganisms on the surfaces of objects, such as tooth brushes, dentures, dental retainers, contact lenses, bandages, dressings, medical devices, etc., by applying gallium compounds to the surfaces of the objects<!-- EPO <DP n="7"> --> to disinfect them or to prevent them from contamination with pathogenic microorganisms. In yet another aspect, methods are disclosed for controlling the growth of iron-dependent pathogenic microorganisms in foods, including grains (<i>e.g.,</i> corn, wheat, rice, barley, and the like), vegetables (<i>e.g</i>., lettuce, spinach, potatoes, and the like), animal products, (<i>e.g.,</i> fish, eggs and meat, and the like), by directly applying gallium compounds to the same by soaking, washing and/or spraying.</p><p id="p0012" num="0012">In another aspect, methods are disclosed for controlling the growth of iron-dependent pathogenic microorganisms by applying gallium compounds to host organisms in need thereof in combination with probiotic microorganisms. Such probiotic microorganisms include, but are not limited to, non-pathogenic species of the genera <i>Lactobacillus, Lactococcus, Bifidobacterium,</i> and so forth, whose growths are not affected by the presence of gallium.</p><p id="p0013" num="0013">The present invention further provides formulations comprising gallium compounds for controlling the growth of iron-dependent pathogenic microorganisms. In a specific embodiment, the gallium compounds are formulated as toothpaste, a mouthwash, or a gargle for the application to the oral cavity. Further disclosed are gallium compounds formulated as ointments, lotions, creams, gels, solutions, eye drops, aerosols, and so forth, for topical or local applications. In yet another specific aspect, the gallium compounds are formulated as a coating to the surfaces of an object to disinfect the same and/or to treat the infections in a wearer of the object (<i>e.g.,</i> contact lenses to treat ocular infections). In yet another preferred embodiment, the formulations of the present invention may contain probiotic microorganisms in addition to gallium compounds.</p><p id="p0014" num="0014">In yet another aspect, animal feeds are disclosed comprising gallium compounds with or without probiotics.</p><heading id="h0003">3.1. Definitions</heading><!-- EPO <DP n="8"> --><p id="p0015" num="0015">The term "subject" refers to an animal, including a fowl (<i>e.g.,</i> chickens, turkeys, and the like), and a mammal such as a non-primate (<i>e.g.,</i> cows, pigs, horses, cats, dogs, rats, etc.) and a primate (<i>e.g</i>., monkey and human), most preferably a human.</p><p id="p0016" num="0016">The term "topically", as opposed to "systemically", as used herein refers to an application of the gallium compounds to a definite area of the body of a subject and is interchangeably used with the term "locally." The term topically may refer to an application of the gallium compounds directly to an external area of the body, such as skin and eye as well as oral cavity, nasal cavity and vagina. The term topically may also refer to an application of the gallium compounds directly to a definite area inside the body which is exposed to an outer environment, for example, by injury or during surgery.</p><p id="p0017" num="0017">The term "superficially" as used herein refers to an application of the gallium compounds to the surfaces of an inanimate or animate object. The term superficially may refer to an application of the gallium compounds to the surfaces of an inanimate or animate object by coating. Alternatively, the term superficially may refer to an application of the gallium compounds to the surfaces of an inanimate or animate object by soaking the object in a solution of the gallium compounds or adhering/bonding the gallium compounds to the surface of the object.</p><p id="p0018" num="0018">The term "prophylactically effective amount" as used herein refers to that amount of the gallium compounds sufficient to prevent a disease or disorder associated with pathogenic microorganisms at a given site. A prophylactically effective amount may refer to the amount of the gallium compounds sufficient to prevent or suppress the growth of pathogenic microorganisms or kill pathogenic microorganisms at a given site.</p><p id="p0019" num="0019">The term "therapeutically effective amount" as used herein refers to that amount of the gallium compounds sufficient to treat, manage or ameliorate a disease or disorder caused by pathogenic organisms at affected sites. A therapeutically<!-- EPO <DP n="9"> --> effective amount may refer to the amount of the gallium compounds sufficient to reduce the number of pathogenic microorganisms, to suppress the growth of pathogenic microorganisms (<i>i.e</i>., stasis), or to kill pathogenic microorganisms at the affected sites. Further, a therapeutically effective amount of the gallium compounds means that the amount of the gallium compounds alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment, management, or amelioration of a disease or disorder.</p><p id="p0020" num="0020">The term "effective amount" as used herein in one aspect refers to that amount of the gallium compounds sufficient to control the growth of pathogenic microorganisms on the surfaces of inanimate objects. The term may refer to that amount of the gallium compounds sufficient to reduce the number of pathogenic microorganisms, to suppress the growth of pathogenic microorganisms (<i>i.e</i>., stasis), or to kill pathogenic microorganisms (<i>i.e</i>., disinfect) on the surfaces of objects. The term may also refer to that amount of the gallium compounds sufficient to prevent pathogenic microorganisms from attaching themselves to or colonize onto the surfaces of the objects. The term "effective amount' as used herein in another aspect in relation to animal feeds refers to that amount of the gallium compounds sufficient to promote animal growth and prevent infections when fed to the animals.</p><p id="p0021" num="0021">The term "probiotics" as used herein refers to viable microorganisms which alter the microflora by implantation or colonization in or onto the host, thereby exerting beneficial health effects on the host. The beneficial health effects of probiotics may be exerted particularly successfully in the environment which is hostile to pathogenic organisms but favorable for probiotics so that the growth of the probiotics outweigh that of the pathogenic organisms. Some examples of probiotics are non-pathogenic species of genera <i>Lactobacillus, Lactococcus, Peptostreptococcus, Bifidobacterium,</i> and so forth.</p><heading id="h0004">4. DESCRIPTION OF FIGURES</heading><!-- EPO <DP n="10"> --><p id="p0022" num="0022"><figref idrefs="f0001">Fig.1</figref> is a diagram showing a mechanism by which microorganisms take in iron or gallium.</p><heading id="h0005">5. DETAILED DESCRIPTION OF THE INVENTION</heading><heading id="h0006">5.1. Iron Transport and Gallium</heading><p id="p0023" num="0023">It is a well-known fact that most microorganisms, with a few exceptions <i>(e.g., Lactobacillus spp. --- see</i> <nplcit id="ncit0023" npl-type="s"><text>Archibald, 1983, FEMS Microbiol Lett 19:29-32</text></nplcit>; <nplcit id="ncit0024" npl-type="s"><text>Weinberg, 1997, Perspectives in Biology and Medicine 40(4):578-583</text></nplcit>; and <i>Borrelia burgdorferi --- see</i> <nplcit id="ncit0025" npl-type="s"><text>Posey et al., 2000, Science 288:1651-1653</text></nplcit>), require iron for their survival (<nplcit id="ncit0026" npl-type="s"><text>Weinberg, 1978, Microbiol Rev 42:45-66</text></nplcit>; <nplcit id="ncit0027" npl-type="s"><text>Neilands, 1972, Struct Bond 11:145-170</text></nplcit>). Despite the fact that iron is one of the most abundant metals, its availability to microorganisms is limited due to its existence as insoluble compounds (oxides-hydroxides) in aerobic environments (Guerinot, 1994, <i>supra;</i><nplcit id="ncit0028" npl-type="s"><text> Spiro, et al., 1966, J Ant Chem Soc 88:2721-2725</text></nplcit>; <nplcit id="ncit0029" npl-type="b"><text>Vander Helm et al., 1994, In Metal ions in fungi vol. 11, pp. 39-98, Marcel Dekker, Inc. New York, NY</text></nplcit>). Accordingly, microorganisms, such as bacteria and fungi as well as parasites, have developed various mechanisms in order to acquire iron in the face of its limited availability in the environment (Howard, 1999, <i>supra</i>).</p><p id="p0024" num="0024">One such mechanism is the synthesis of potent iron-chelating compounds called siderophores. Microorganisms produce siderophores, which bind Fe<sup>3+</sup> in the environment and are transported into the cells via specific transport systems, where Fe<sup>3+</sup> is released as Fe<sup>2+</sup> and then stored. Known siderophores include hydroxamates, such as rhodotorulic acid, coprogens, ferrichromes, and fusarinines; polycarboxylates; phenolates-catecholates and desferioxamine (Howard, 1999, <i>supra</i>). Other mechanisms include direct internalization of iron complexed with siderophores or host iron transporters (<i>e.g</i>., transferrin and lactoferrin), membrane-associated reductase mechanisms, and receptor-mediated mechanisms as well as membrane-mediated direct-transfer mechanisms (Howard, 1999, <i>supra;</i> <nplcit id="ncit0030" npl-type="s"><text>Crosa, 1997, Microbiol Mol Biol Rev 61:319-336</text></nplcit>; <nplcit id="ncit0031" npl-type="s"><text>Payne, 1994, Methods Enzymol 235:329-344</text></nplcit>). The<!-- EPO <DP n="11"> --> availability of iron through these mechanisms is closely linked to the virulence of microorganisms (<nplcit id="ncit0032" npl-type="s"><text>Litwin et al., 1993, Clin Microbiol Reviews 6(2):137-149</text></nplcit>), and each organism may have multiple alternative mechanisms for obtaining iron from iron-scarce environments to support its growth and survival (for example, <i>see</i> <nplcit id="ncit0033" npl-type="s"><text>Spatafora et al., 2001, Microbiology 147:1599-1610</text></nplcit>).</p><p id="p0025" num="0025">It has been reported that gallium ion (Ga<sup>3+</sup>) and ferric ion (Fe<sup>3+</sup>) have strong biochemical similarities, in particular, with regard to their binding to proteins and chelators. These similarities are mainly attributed to their comparable ionic radii and the degrees of ionic (electrostatic) versus covalent contributions to bonding (for review, <i>see</i> Bernstein, 1998, <i>supra</i>). Because of these similarities, Ga<sup>3+</sup> can mimic Fe<sup>3+</sup> in various biological processes. For example, Ga<sup>3+</sup> binds to transferrin <i>(see,</i> for example, <nplcit id="ncit0034" npl-type="s"><text>Clausen et al., 1974, Cancer Res 34:1931-1937</text></nplcit>; <nplcit id="ncit0035" npl-type="s"><text>Vallabhajosula et al., 1980, J Nucl Med 21:650-656</text></nplcit>) and is transported into the cell via transferrin-mediated endocytosis (<nplcit id="ncit0036" npl-type="s"><text>Chitambar, 1987, Cancer Res 47:3929-3934</text></nplcit>).</p><p id="p0026" num="0026">Without intending to be bound by theory, it is believed that Ga<sup>3+</sup> may competitively bind to siderophores and be easily taken up by microorganisms, where it can disrupt DNA and protein syntheses or bind to bacterial proteins and impair the growth of the microorganisms, thereby eventually leading to the stasis or death of the organisms. Alternatively, it is possible that Ga<sup>3+</sup> may occupy membrane-reductases of the microorganisms and prevent Fe<sup>3+</sup> from binding to the reductases to be reduced to Fe<sup>2+</sup>, which would be more bioavailable than Fe<sup>3+</sup>. Since the uptake of gallium does not immediately kill the microorganisms but rather leads to an initial stasis <i>(i.e.,</i> a state where the growth or multiplication of microorganisms is inhibited), it has a reduced risk for generating resistant microorganisms.</p><p id="p0027" num="0027">The present invention takes advantage of these characteristics of gallium compounds and provides methods and formulations for controlling the growth of pathogenic microorganisms to treat or prevent infections caused by such pathogens.<!-- EPO <DP n="12"> --></p><heading id="h0007">5.2. Gallium Compounds</heading><p id="p0028" num="0028">Gallium compounds disclosed herein include any gallium-containing compounds that are pharmaceutically acceptable and safe for mammalian use, in particular, for human use. Gallium compounds have been used diagnostically and therapeutically in humans and are known to be very safe for human use (see Poster <i>et al.,</i> 1986, <i>supra</i>; <nplcit id="ncit0037" npl-type="s"><text>Todd et al., 1991, Drugs 42:261-273</text></nplcit>; <nplcit id="ncit0038" npl-type="s"><text>Johnkoff et al., 1993, Br J Cancer 67:693-700</text></nplcit>).</p><p id="p0029" num="0029">Pharmaceutically acceptable gallium compounds suitable for use in the present invention include, but not by way of limitation, gallium nitrate, gallium maltolate, gallium citrate, gallium phosphate, gallium chloride, gallium fluoride, gallium carbonate, gallium formate, gallium acetate, gallium sulfate, gallium tartrate, gallium oxalate, gallium oxide, and any other gallium compounds which can safely provide effective levels of element gallium in various applications. Further disclosed are gallium complexes, such as gallium pyrones, gallium pyridones, and gallium oximes, as well as gallium bound to proteins, such as transferrin and lactoferrin, or gallium bound to siderophores, such as hydroxamates, polycarboxylates, and phenolates-catecholates, desferioxamine and other iron-chelators, such as cysteine, α-keto acids, hydroxy acids and pyridoxal isonicotinyl hydrazone class <i>(</i><nplcit id="ncit0039" npl-type="s"><text>Richardson et al., 1997, Antimicrobial Agents and Chemotherapy 41(9):2061-2063</text></nplcit>) and the like.</p><p id="p0030" num="0030">The therapeutically effective amount (<i>i.e</i>., dosage) of a gallium compound can vary based on the nature and severity of the disease or disorder to be treated, the location of the affected area, the age and immunological background of a subject, the types of gallium compound to be used, as well as other factors apparent to those skilled in the art. Typically, a therapeutically effective amount of a gallium compound can be that amount which gives gallium ion concentration, at the site of the application, of at least about 1 <i>µ</i>M, at least about 50 <i>µ</i>M, at least about 100 <i>µ</i>M, at least about 500 <i>µ</i>M, at least about 1 mM, at least about 10 mM, at least about 50 mM,<!-- EPO <DP n="13"> --> at least about 100 mM, at least about 200 mM, up to about 500 mM. Due to gallium's low toxicity, the amount may be liberally increased to more than 500 mM but less than that amount which causes any toxicity. For reference, it has been reported that healthy adults can tolerate at least about 200 mg/m<sup>2</sup>/day gallium nitrate intravenous infusion for at least 7 days (see Schlesinger <i>et al., supra</i>).</p><p id="p0031" num="0031">The prophylactically effective amount of a gallium compound may be that amount sufficient to prevent a disease or disorder associated with pathogenic microorganisms and may vary based on the location of the affected area, the types and the number of the pathogenic organisms in the area, the types of gallium compound to be used, as well as on the methods of application and other factors apparent to those skilled in the art. Typically, the prophylactically effective amount of a gallium compound may be that amount which gives gallium ion concentration, at the site of the application, of at least about 0.1 <i>µ</i>M, at least about 50 <i>µ</i>M, at least about 100 <i>µ</i>M, at least about 500 <i>µ</i>M, at least about 1 mM, at least about 10 mM, at least about 50 mM, at least about 100 mM, up to about 200 mM. Again, the amount of a gallium compound for prophylactic purposes may be liberally increased to more than 200 mM but less than the amount that causes any toxicity.</p><p id="p0032" num="0032">The effective amount of a gallium compound sufficient to control the growth of pathogenic microorganisms on the surfaces of inanimate objects may vary depending on the types of the objects, frequencies of their use, frequencies of their exposure to pathogenic organisms and other factors evident to those skilled in the art. Typically, the effective amount of a gallium compound for this application may be the amount which gives gallium ion concentration of at least about 50 mg/m<sup>2</sup>, at least about 100 mg/m<sup>2</sup>, at least about 200 mg/m<sup>2</sup>, at least about 300 mg/m<sup>2</sup>, at least about 500 mg/m<sup>2</sup>, at least about 600 mg/m<sup>2</sup>, at least about 700 mg/m<sup>2</sup>, at least about 800 mg/m<sup>2</sup>, at least about 900 mg/m<sup>2</sup>, or at least about 1 g/m<sup>2</sup>, on the surface area of the object.</p><heading id="h0008">5.3. Formulation of Gallium Compounds</heading><!-- EPO <DP n="14"> --><p id="p0033" num="0033">The gallium compounds suitable for the present invention can be formulated in various forms depending on their applications. Accordingly, the present invention provides formulations comprising gallium compounds for controlling growth of iron-dependent pathogenic microorganisms. In a specific embodiment, the gallium compounds are formulated as toothpaste, a mouthwash, a gel or a gargle for the application to the oral cavity. Further disclosed are gallium compounds formulated as ointments, lotions, creams, gels, solutions, aerosols, suppositories and so forth, for topical or local applications. Any other formulations typically used for topical or local applications are also applicable.</p><p id="p0034" num="0034">In another aspect, the formulations may further comprise probiotic microorganisms in addition to gallium compounds. When such formulations are applied to the affected area, probiotics can take over the microflora while the gallium compounds reduce or inhibit the growth of the pathogenic organisms, or kill the pathogenic organisms.</p><p id="p0035" num="0035">The gallium compound formulations of the present invention may further contain other active or inactive ingredients. For toothpaste, such other ingredients include, but are not limited to, potassium nitrate (to reduce tooth sensitivity), fluorides, abrasives, such as hydrated silica, surfactants, such as sodium lauryl sulfate, and ammonium lauryl sulfate, sequestering agents (to remove calcium and magnesium from saliva), such as tetrasodium pyrophosphate (TSPP), polymers, such as acrylic PVM/MA copolymer, polyethylene glycol (PEG), and polypropylene glycol (PPG), tooth whiteners, such as sodium carbonate peroxide, sweeteners, baking soda, as well as other anti-bacterial agents and fillers. For creams and lotions, such other ingredients include, but are not limited to, emollients, moisturizers, vitamins, antioxidants, surfactants, and so forth.</p><heading id="h0009">5.4. Dental Caries</heading><!-- EPO <DP n="15"> --><p id="p0036" num="0036">The use of fluoride-containing products as well as the fluoridation of public water in the past 20 years have reduced the prevalence of dental caries in the U.S (for review of this subject, <i>see</i> <nplcit id="ncit0040" npl-type="s"><text>Featherstone, 2000, JADA 131:887-898</text></nplcit>). However, the recent report has shown that about 94% of all dentate adults, 18 years old or older, in the U.S. had evidence of treated or untreated coronal caries (<nplcit id="ncit0041" npl-type="s"><text>Winn et al., 1996, J Dent Res 75:642-51</text></nplcit>), thus indicating that tooth decay still remains a major problem in adults as well as in children in the U.S.</p><p id="p0037" num="0037">Dental caries is a transmissible disease which is bacterially generated in combination with other pathological factors, such as reduced salivary function and frequency of use of fermentable carbohydrates (Featherstone, 2000, <i>supra</i>). Among resident oral bacteria, high levels of <i>Streptococcus mutans</i> and lactobacilli constitute the major etiological factors in caries formation. However, an antibacterial approach has not been the focus of regular oral hygiene measures taken in the U.S. to prevent or halt the progression of dental caries. An exception is a prescription of chlorhexidine gluconate rinse or gel for patients with high levels of bacteria; but it is difficult for clinicians to determine the levels of cariogenic bacteria in the mouth.</p><p id="p0038" num="0038"><i>Streptococcus mutants (S. mutans</i>) is also known to require iron uptake for its growth and survival and expresses several iron-responsive proteins (<nplcit id="ncit0042" npl-type="s"><text>Spatafora et al., 2001, Microbiology 147:1599-1610</text></nplcit>). <i>A fimA,</i> one of the iron-responsive proteins, null mutation was not lethal in S. <i>mutans,</i> indicating that other mechanisms for iron uptake and transport are operating in this pathogenic organism (Spatafora <i>et al.,</i> 2001, <i>supra).</i> It has been reported that <i>S. mutans</i> does not excrete a readily detectable phenolate or hydroxamate siderophores, but it has a membrane-reductase which reduces ferric ion to ferrous ion, which is subsequently transported into the cell by a membrane ferrous-translocating system (<nplcit id="ncit0043" npl-type="s"><text>Evans et al., 1986, J of Bacteriol 168(3):1096-1099</text></nplcit>). Thus, iron uptake and transport seem to be crucial for cariogenic virulence of the organism.<!-- EPO <DP n="16"> --></p><p id="p0039" num="0039">Accordingly, the present invention provides a method for preventing dental caries, comprising applying a prophylactically effective amount of a gallium compound to a tooth surface and an oral cavity of a subject. In a preferred embodiment, the gallium compound is formulated as a toothpaste comprising a gallium compound and is applied to the tooth surface and oral cavity by brushing. In another preferred embodiment, the gallium compound is formulated as a mouthwash comprising a gallium compound and applied to the tooth surface by rinsing the oral cavity. In another preferred embodiment, the gallium compound may be formulated as an ointment or a gel to be applied to a tooth surface.</p><heading id="h0010">5.5. Vaginal Infections</heading><p id="p0040" num="0040">Vaginal infections (or vaginitis) are among the most common medical concerns for women. Among vaginal infections, the most common is a yeast infection caused by the overgrowth of <i>Candida albicans (C. albicans</i>), which is a normal resident in the vagina in small numbers. It has been reported that siderophore uptake by <i>sit1</i> (<u>s</u>iderophores iron <u>t</u>ransport 1) gene product is required for C. <i>albicans</i> to invade and penetrate epithelial layers, indicating that iron uptake is directly linked to virulence factors of the organism (<nplcit id="ncit0044" npl-type="s"><text>Heymann et al., 2002, Infection and Immunity 70(9):5246-5255</text></nplcit>). Thus, replacing iron with gallium compounds can effectively control the growth of C. <i>albicans</i> in the vagina. Accordingly, in a specific aspect, a method is disclosed for treating vaginal yeast infection comprising applying a gallium compound to the vagina of a subject. The gallium compound may be formulated as creams, ointments, gels, douches, or suppositories.</p><p id="p0041" num="0041">For treating other types of vaginal infections, including, but not by way of limitation, bacterial vaginosis caused by pathogenic bacteria, such as <i>Gardnerella vaginalis, Bacteroides spp., Mobiluncus spp.,</i> and <i>Mycoplasma hominis,</i> and parasitic vaginosis caused by<!-- EPO <DP n="17"> --> <i>Trichomonas vaginalis,</i> the gallium compounds may be applied in various formulations to the vagina.</p><p id="p0042" num="0042">Since most of the vaginal infections are the results of changes in the populations of the vaginal normal flora, populating the area with non pathogenic normal residents, such as <i>Lactobacillus spp.,</i> can also prevent the outgrowth of the pathogenic organisms. Accordingly, in one aspect, a method is disclosed for treating vaginal infections, comprising applying a gallium compound in combination with a probiotic, such as <i>Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus leichmannii, Lactobacillus johnsonni, Lactobacillus</i> and <i>delbrueckii.</i></p><heading id="h0011">5.6. Disinfection of Inanimate or Animate Objects</heading><p id="p0043" num="0043">Antimicrobial activities of the gallium compound can be also used for disinfecting or protecting the surfaces of inanimate or animate objects from microbial contaminations. Accordingly, a method is disclosed for controlling a growth of microorganisms on a surface of an inanimate or animate object, comprising applying an effective amount of a gallium compound to a surface of the object.</p><p id="p0044" num="0044">For example, toothbrushes, dentures and dental retainers often harbor carried-over oral microorganisms and it is desirable to prevent the growth of such organisms on the surfaces of these products from oral hygiene viewpoints. Accordingly, in a specific aspect, a method is disclosed for disinfecting the objects, such as a toothbrush, a denture, a dental retainer, and other dental devices, by applying an effective amount of a gallium compoundto a surface of the object. The gallium compounds may be applied to the surface of the object by dipping, brushing, spraying or coating. The coating may be based on a certain polymer that allows slow diffusion of the gallium compound at such a rate that it prevents microorganisms from growing on the surface of the object. Examples of polymer coatings include, but are not limited to, hydroxyapatite, polymethacrylates,<!-- EPO <DP n="18"> --> tricalcium phosphate, polyanhydrides, hydrocarbon elastomers, methyl- and ethyl cellulose, hydroxypropyl cellulose, cellulose acetate, phthalate, and so forth. Alternatively, the gallium compounds can be incorporated into materials, for example, the polymers (<i>e.g.,</i> thermoplastics, thermoset resins, and the like), metals, and the like, which form the object itself (<i>e.g.,</i> bristles of a toothbrush, a catheter, medical equipment, injection needles, and the like).</p><p id="p0045" num="0045">In another specific aspect, a method is disclosed for disinfecting contact lenses by applying an effective amount of a gallium compound to a surface of the lenses. The lenses may be disinfected by dipping them in the gallium compound solution, or by coating their surfaces with or without a certain polymer containing the gallium compounds as described above.</p><p id="p0046" num="0046">In another specific aspect a method is disclosed for disinfecting skin surfaces of a subject, comprising applying the gallium compounds to the same, for example, as soap, shampoo, skin disinfectant (<i>e.g.,</i> hand), and the like. Preferably, the gallium compounds are applied to the skin surfaces in the form of cream, lotion, solution, aerosol, or ointment.</p><p id="p0047" num="0047">In another specific aspect a method is disclosed for controlling the growth of microorganisms in drinks and foods, including grains, vegetables, animal products, such as fish, eggs, dairy products, meat, and the like, comprising applying the gallium compound directly to the same by washing, soaking and/or spraying. Such a treatment of foods can effectively protect the consumers from food poisoning.</p><p id="p0048" num="0048">Also disclosed are medical implants, bandages, wound dressings which are surface-coated with the gallium compounds.</p><p id="p0049" num="0049">Furthermore, a method is disclosed for controlling a microbial growth on various environmental surfaces in households, hospitals, schools, etc., by applying the gallium compounds to the same. The gallium<!-- EPO <DP n="19"> --> compounds can be used against any gallium-susceptible pathogenic microorganisms as discussed throughout the present specification <i>(see</i> Section 3 and Subsections 5.4 and 5.5, <i>supra,</i> and Subsections 5.7 and 5.8, <i>infra</i>), including the microorganisms that are known to have become resistant to first-line antibiotics. Such microorganisms include <i>Escherichia coli</i> O157 (a causative organism for gastroenteritis, haemorrhagic colitis or urinary and genital tract infections), vancomycin-resistant <i>Enterococcus faecalis</i> (a causative organism for endocarditis, urinary tract infections, and wound infections), methicillin resistant <i>Staphylococcus aureus</i> (MRSA; a causative organism for various skin infections, eye infection, wound infections, and so forth), <i>Salmonella typhi</i> (the causative organism for typhoid fever), and the like. The applications of the gallium compounds to various surfaces are cost effective and significantly reduce microbial contaminations in the environment without increasing the development of antibiotic-resistant microorganisms.</p><heading id="h0012">5.7. Animal Feeds</heading><p id="p0050" num="0050">The use of antibiotics in animal feeds to boost animal growth and prevent infections has caused in a major way the development of drug-resistant bacteria. Such a use of antibiotics in poultry and beef industries has resulted in the emergence of antibiotics-resistant pathogens among species of genera <i>Salmonella, Campylobacter, Shigella, Brucella,</i> and so forth. Thus, some countries are in the process of banning the use of antibiotics in animal feeds.</p><p id="p0051" num="0051">As discussed above, gallium compounds have less risks of generating drug-resistant pathogens than do regular antibiotics and, therefore, are viable alternatives to the conventional antibiotics. Accordingly, the present specification discloses an animal feed comprising an effective amount of a gallium compound. The effective amount of a gallium compound in an animal feed sufficient to promote animal growth and prevent infections can be readily determined based on the therapeutic or prophylactic dosages of the gallium compounds described in the<!-- EPO <DP n="20"> --> previous sections <i>(see</i> Subsection 5.2) and such a determination is within the ability of those skilled in the art.</p><p id="p0052" num="0052">In a specific aspect, the animal feed may further comprise probiotics. The health benefits of probiotics are discussed in Subsections 3.1 and 5.3. Typical probiotic compositions and methods for increasing the number of probiotic or resident microorganisms in the gastrointestinal tract of an animal are disclosed, for example, in <patcit id="pcit0011" dnum="US6221350B"><text>U.S. Patent No. 6,221,350</text></patcit>.</p><heading id="h0013">5.8. Miscellaneous Applications</heading><p id="p0053" num="0053">Gallium compounds may be utilized in many different applications other than those described in the previous sections. For example, gallium compounds may be applied topically or directly to a body area, including an open wound and an internal organ or tissue exposed to an outer environment during surgery in addition to an external area, that needs to be protected from or is afflicted with various infections caused by pathogenic organisms. Such infections include, but not by way of limitation, skin infections, such as cellulites, folliculitis, boils, carbuncles, erysipelas, impetigo, erythrasma, paronychia, staphylococcal scalded skin syndrome, candidiasis (<i>e.g.,</i> oral thrush), ring worm, tinea versicolor, etc. as well as eye infections, such as blepharitis, hordeola, conjunctivitis, etc., and nasal infections. Causative organisms for skin infections include, but are not limited to, species of <i>Staphylococcus,</i> such as <i>S. aureus</i> and <i>S. epidermidis;</i> Group A streptococci, such as <i>Streptococus pyogenes; Pseudomonas aeruginosa,</i> and the like. Typical yeasts or fungi that cause skin infections include <i>Candida albicans,</i> species of genus <i>Microsporon,</i> such as <i>M. auduini</i> and <i>M. canis;</i> species of <i>Trichophyton,</i> such as <i>T. metagrophyte</i> and <i>T. tonsurans,</i> and the like. Causative organisms for eye infections include <i>Staphylococcus aureus, Streptococcus pyogerzes, Haemophilus influenzae, Chlamydia trachomatis, Neisseria gonorrhoeae, Propionibacterium spp., Nocardia spp., Bacteroides spp, Fusarium spp.</i> and so forth. Nasal infections caused by <i>Streptococcus penumoniae</i> may lead to ear infection, sinusitis, bronchitis, pneumonia, etc. The infections caused by these organisms have<!-- EPO <DP n="21"> --> become more and more common because of the development of drug-resistant microorganisms, such as methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), as well as the increased number of immunocompromised individuals due to HIV infection or AIDS, organ transplants, treatments for autoimmune diseases, and so forth. Thus, the applications of gallium compounds for human uses as well as veterinarian uses are very beneficial especially in view of their low toxicity and low risks for generating resistant microorganisms. Other applications in the fields of food industries, agricultural industries, fishing industries and so forth are also possible.</p><heading id="h0014">6. EXAMPLES</heading><heading id="h0015"><u>Susceptibility of Microorganisms to Gallium</u></heading><p id="p0054" num="0054">Susceptibility of various microorganisms to gallium was tested by determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for each microorganism using gallium nitrate. In general, MIC is determined by (i) mixing a series of broths, each containing a standard number of microorganisms, with serially diluted solutions of the gallium compound; and (ii) determining the MIC, after incubation, that is the lowest concentration of the gallium compound that has inhibited the growth of the microorganism. The lower the MIC, the more susceptible the organism is. The MBC is determined by subculturing an aliquot of each sample from the MIC test on an appropriate agar plate containing no gallium compound. After incubation, the MBC is determined to be the lowest concentration of the gallium compound at which no growth is observed.</p><p id="p0055" num="0055">Specifically, in the present experiment, two grams of gallium nitrate powder were dissolved in 10 ml of filter-sterilized deionized water and the resulting 20% (w/v) (<i>i.e</i>.<i>,</i> 200 mg/ml) solution was once again filter-sterilized. Two-fold serial dilutions were prepared in sterile deionized water down to 0.156% (<i>i.e.,</i> 1.56 mg/ml) for the tests for the most organisms, except for the tests for <i>Candida albicans</i> and<!-- EPO <DP n="22"> --> <i>Streptococcus mutans,</i> in which 10%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, 0.005% and 0.001% of gallium nitrate solutions were prepared.</p><p id="p0056" num="0056">Table 1 shows the list of microorganisms tested for MIC and MBC. All organisms were obtained from the American Type Culture Collection (ATCC), Manassas, VA. Each microorganism was picked from the seed culture (<i>see</i> Table 1) and inoculated in an appropriate type of broth to obtain a 0.5 McFarland turbidity standard. The standard suspension of the microorganism was then diluted to 1:100 with the broth and used for the tests.<!-- EPO <DP n="23"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title>Table 1</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="69mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="69mm"/><thead><row><entry align="center" valign="middle">TEST ORGANISM</entry><entry align="center" valign="middle">ATCC #</entry><entry align="center" valign="middle">SEED CULTURE</entry></row></thead><tbody><row><entry align="center" valign="middle"><i>Candida albicans</i></entry><entry align="center" valign="middle">10231</entry><entry valign="middle">On Sabouraud dextrose agar, at 25-30°C for 24-48 hours.</entry></row><row><entry align="center" valign="middle"><i>Streptococcus mutans</i></entry><entry align="center" valign="middle">25175</entry><entry valign="middle">On blood agar, at 35-37°C for 24-48 hours, with CO<sub>2</sub>.</entry></row><row><entry align="center" valign="middle"><i>Porphyromonas gingivalis</i></entry><entry align="center" valign="middle">33277</entry><entry valign="middle">On Brucella blood agar, at 35-37°C for 7 days under anaerobic conditions.</entry></row><row><entry align="center" valign="middle"><i>Pseudomonas aeruginosa</i></entry><entry align="center" valign="middle">15442</entry><entry morerows="4" valign="middle">On tryptic soy agar with 5% sheep blood (BAP), at 35-37°C for 24-48 hours under aerobic conditions.</entry></row><row><entry align="center" valign="middle">Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)<sup>a</sup></entry><entry align="center" valign="middle">33592</entry></row><row><entry align="center" valign="middle">Vancomycin-resistant <i>Enterococcus faecalis</i> (VRE)<sup>b</sup></entry><entry align="center" valign="middle">51575</entry></row><row><entry align="center" valign="middle"><i>Escherichia coli</i> O157:H7</entry><entry align="center" valign="middle">35150</entry></row><row><entry align="center" valign="middle"><i>Salmonella typhi</i></entry><entry align="center" valign="middle">6539</entry></row><row><entry align="center" valign="middle"><i>Campylobacter jejuni</i></entry><entry align="center" valign="middle">29428</entry><entry valign="middle">On Brucella agar with 5% sheep blood, at 35-37°C for 48 hours under microaerophilic conditions (CampyPak™ by BBL Microbiology Systems, Cockeysville, Md).</entry></row></tbody></tgroup><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="69mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="69mm"/><tbody><row><entry namest="col1" nameend="col3" align="justify">a. Antibiotics resistance of the organism was confirmed by CLSI (Clinical Laboratory Standards Institute) Oxacillin disk-diffusion test. The zone of inhibition was 6 mm (CLSI Oxacillin resistant range: s 10 mm).<br/>
b. Antibiotics resistance of the organism was confirmed by CLSI Vancomycin disk-diffusion test. The zone of inhibition was 10 mm (CLSI Vancomycin resistant range: ≤ 14 mm).</entry></row></tbody></tgroup></table></tables></p><p id="p0057" num="0057">Each microorganism was tested in duplicate by either a microdilution broth method in 96-well plates (<i>i.e</i>., 0.1 ml of the gallium nitrate solution mixed with 0.1 ml of the microorganism suspension) or a macrodilution broth method in test tubes (<i>i.e</i>.,1 ml of the gallium nitrate solution mixed with 1 ml of the microorganism suspension) as follows:<!-- EPO <DP n="24"> --></p><p id="p0058" num="0058">Microdilution broth method: <i>Candida albicans; Streptococcus mutans; Escherichia coli</i> O157:H7; and <i>Campylobacter jejuni.</i></p><p id="p0059" num="0059">Macrodilution broth method: Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA); Vancomycin-resistant <i>Enterococcus faecalis</i> (VRE); <i>Salmonella typhi; Pseudomonas aeruginosa;</i> and <i>Porphyromonas gingivalis.</i></p><p id="p0060" num="0060">The growth of the microorganisms were determined by visual observation of turbidity in the samples.</p><p id="p0061" num="0061">The following controls were incubated together with the test samples:
<ul><li>Viability control: A mixture of equal volumes of deionized water and an appropriate broth inoculated with a test microorganism but without gallium nitrate; and</li><li>Sterility control: A mixture of equal volumes of deionized water and an appropriate broth without either microorganisms or gallium nitrate.</li></ul></p><p id="p0062" num="0062">Purity of each microorganism was confirmed by streaking an appropriately diluted suspension of the microorganism onto an appropriate agar plate to obtain isolated colonies and observing colony morphology.</p><p id="p0063" num="0063">The concentrations of microorganisms in the suspension used in MIC test were determined by inoculating serial dilutions of the suspensions onto appropriate agar plates and counting the number of colonies.</p><p id="p0064" num="0064">To determine MBC, 10 <i>µ</i>l of each sample used in MIC were inoculated onto an appropriate agar plate and incubated. The lowest concentration of the gallium nitrate that showed no growth was determined to be the MBC.</p><p id="p0065" num="0065">The results are shown in Table 2 below.<!-- EPO <DP n="25"> -->
<tables id="tabl0002" num="0002"><table frame="all"><title>Table 2</title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="30mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="23mm"/><colspec colnum="4" colname="col4" colwidth="23mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="19mm"/><colspec colnum="7" colname="col7" colwidth="19mm"/><thead><row><entry align="center" valign="middle">Test Organism</entry><entry align="center">Broth (MIC)</entry><entry align="center">Agar Plate (MBC)</entry><entry align="center">Incubation Condition</entry><entry align="center" valign="middle">Final Concentration of Organism (CFU/ml)</entry><entry align="center" valign="middle">MIC (mg/ml)</entry><entry align="center" valign="middle">MBC (mg/ml)</entry></row></thead><tbody><row><entry align="center" valign="middle"><i>Candida albicans</i></entry><entry align="center">Sabouraud Dextrose</entry><entry align="center">Sabouraud dextrose agar</entry><entry align="center">At 27°C for 48 hours</entry><entry align="center">9.75 x 10<sup>5</sup></entry><entry align="center">10</entry><entry align="center">&gt; 100</entry></row><row><entry align="center" valign="middle"><i>Streptococcus mutans</i></entry><entry align="center">Brain Heart Infusion</entry><entry align="center">Blood agar</entry><entry align="center">At 36°C For 48 hours</entry><entry align="center">4.1 x 10<sup>6</sup></entry><entry align="center">ND*</entry><entry align="center">5.0</entry></row><row><entry align="center" valign="middle"><i>Porphyromonas gingivalis</i></entry><entry align="center">Fluid Thioglycollate</entry><entry align="center">Brucella blood agar</entry><entry align="center">At 36°C for 14 days (plate controls: for 5 days)</entry><entry align="center">7.2 x 10<sup>7</sup></entry><entry align="center">ND</entry><entry align="center">&lt; 0.78</entry></row><row><entry align="center" valign="middle"><i>Pseudomonas aeruginosa</i></entry><entry align="center">Muller Hinton</entry><entry align="center">Tryptic soy agar with 5% sheep blood</entry><entry align="center">At 36°C for 48 hours</entry><entry align="center">7.6 x 10<sup>5</sup></entry><entry align="center">ND</entry><entry align="center">6.25</entry></row><row><entry align="center" valign="middle"><i>Staphylococcus aureus</i> (MRSA)</entry><entry align="center">Muller Hinton</entry><entry align="center">Tryptic soy agar with 5% sheep blood</entry><entry align="center">At 36°C for 48 hours</entry><entry align="center">5.2 x 10<sup>5</sup></entry><entry align="center">ND</entry><entry align="center">12.5</entry></row><row><entry align="center" valign="middle"><i>Enterococcus faecalis</i> (VRE)</entry><entry align="center">Muller Hinton</entry><entry align="center">Tryptic soy agar with 5% sheep blood</entry><entry align="center">At 36°C for 48 hours</entry><entry align="center">3.9 x 10<sup>5</sup></entry><entry align="center">ND</entry><entry align="center">25</entry></row><row><entry align="center" valign="middle"><i>Escherichia coli</i> O157:H7</entry><entry align="center">Muller Hinton</entry><entry align="center">Tryptic soy agar with 5% sheep blood</entry><entry align="center">At 36°C for 48 hours</entry><entry align="center">1.38 x 10<sup>6</sup></entry><entry align="center">ND</entry><entry align="center">6.25</entry></row><row><entry align="center" valign="middle"><i>Salmonella typhi</i></entry><entry align="center">Muller Hinton</entry><entry align="center">Tryptic soy agar with 5% sheep blood</entry><entry align="center">At 36°C for 48 hours</entry><entry align="center">8.3 x 10<sup>5</sup></entry><entry align="center">ND</entry><entry align="center">6.25</entry></row><!-- EPO <DP n="26"> --><row><entry align="center" valign="middle"><i>Campylobacter jejuni</i></entry><entry align="center">Muller Hinton</entry><entry align="center">Tryptic soy agar with 5% sheep blood</entry><entry align="center">At 36°C for 48 hours</entry><entry align="center">4.9 x 10<sup>5</sup></entry><entry align="center">ND</entry><entry align="center">&lt; 0.78</entry></row></tbody></tgroup><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="30mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="23mm"/><colspec colnum="4" colname="col4" colwidth="23mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="19mm"/><colspec colnum="7" colname="col7" colwidth="19mm"/><tbody><row><entry namest="col1" nameend="col7" align="justify">* ND: Not determined due to non-specific turbidity caused by the precipitation of gallium nitrate at some dilutions.</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="27"> --></p><p id="p0066" num="0066">The following examples are intended to illustrate, without limitation, preferred embodiments of the present invention as applied to practical modalities for the prevention and treatment of bacterial and fungal infections.</p><heading id="h0016"><u>Example 1 -</u> Toothpaste Formulation</heading><p id="p0067" num="0067">A toothpaste is formulated to contain gallium nitrate at 50 µM and 0.2% by weight sodium fluoride as active ingredients in the treatment and prevention of dental and periodontal disease. The formulation also contains conventional inactive ingredients including water, sorbitol, glycerin, hydrated silica, polyethyleneglycol, xanthan gum, sodium saccharin, methylparaben, and propylparaben. These are blended in amounts known to those skilled in the art to obtain a toothpaste of appropriate consistency. The formulation canbe packaged in conventional toothpaste tubes, and used in the normal manner.</p><heading id="h0017"><u>Example 2</u> - Treatment of Vaginal Yeast Infection</heading><p id="p0068" num="0068">The gallium compound as described herein is applied to the formulation of suppositories and creams for the treatment of internal and external vaginal yeast infections, respectively, as follows. Gallium citrate at 200 µM is combined with inactive ingredients including, in the case of a suppositories, gelatin, glycerin, lecithin, mineral oil, titanium oxide, and white petrolatum, or, in the case of external creams, benzoic acid, isopropylmyristate, polysorbate 60, potassium hydroxide, propyleneglycol, distilled water and stearyl alcohoL These formulations can be suitably packaged for use in a conventional manner.</p><heading id="h0018"><u>Example 3 -</u> Disinfection of Inanimate Objects</heading><p id="p0069" num="0069">A liquid formulation in a form of an aqueous solution of 5% by weight gallium phosphate and 5% by weight dimethyl benzyl ammonium chloride is prepared and packaged for use in households, hospitals, barber shops and beauty parlors as a surface treatment agent for disinfecting objects whose surfaces are prone<!-- EPO <DP n="28"> --> to acting as sites for the growth of pathogenic organisms. Such a formulation can be used by application to such surfaces in a conventional manner.</p><heading id="h0019"><u>Example 4</u> - Animal Feeds</heading><p id="p0070" num="0070">In the formulation of animal feeds whereby various nutrients and adjuvants are added to grains that are fed to domestic animals, gallium tartrate at 200 mg/kg feed is added to the feed separately or in combination with the aforesaid ingredients to ensure optimal mixing. The gallium tartrate can be applied as an aqueous solution using conventional equipment to achieve dispersal of the gallium tartrate throughout the feed.</p></description><claims mxw-id="PCLM56979260" lang="DE" load-source="patent-office"><!-- EPO <DP n="32"> --><claim id="c-de-01-0001" num="0001"><claim-text>Zahnpasta, umfassend eine Galliumverbindung in einer für die Prophylaxe wirksamen Menge, zur Verwendung bei der Behandlung von Erkrankungen und Störungen in der Mundhöhle, die mit pathogenen Bakterien in Zusammenhang stehen, durch Kontrolle des Wachstums besagter pathogener Bakterien in der Mundhöhle, wobei besagte Verbindung mindestens eine ausgewählt aus der Gruppe bestehend aus Galliumnitrat, Galliummaltolat, Galliumcitrat, Galliumphosphat, Galliumchlorid, Galliumfluorid, Galliumcarbonat, Galliumformiat, Galliumacetat, Galliumsulfat, Galliumtartrat, Galliumoxalat und Galliumoxid ist.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Zahnpasta nach Anspruch 1, wobei besagte Erkrankung oder Störung ausgewählt ist aus der Gruppe bestehend aus Zahnkaries, Plaque, Paradontalerkrankungen, Halitosis und Gingivitis.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Zahnpasta nach Anspruch 1 oder Anspruch 2, wobei die Galliumionenkonzentration am Anwendungsort
<claim-text>i) mindestens etwa 0,1 µM; oder</claim-text>
<claim-text>ii) mindestens etwa 50 µM; oder</claim-text>
<claim-text>iii) mindestens etwa 100 µM<br/>
beträgt.</claim-text></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Zahnpasta nach einem der Ansprüche 1 bis 3, wobei besagtes pathogenes Bakterium mindestens eines ausgewählt aus der Gruppe bestehend aus <i>Streptococcus mutans, Streptococcus sanguis, Streptococcus gordonii, Atopobium parvulum, Porphyromonas gingivalis</i> und <i>Eubacterium sulci</i> ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Mundwasser, umfassend eine Galliumverbindung in einer für die Prophylaxe wirksamen Menge, zur Verwendung bei der Behandlung von Erkrankungen und Störungen in der Mundhöhle, die mit pathogenen Bakterien in Zusammenhang stehen, durch Kontrolle des Wachstums besagter pathogener Bakterien in der Mundhöhle, wobei besagte Verbindung mindestens eine ausgewählt aus der Gruppe bestehend aus Galliumnitrat, Galliummaltolat,<!-- EPO <DP n="33"> --> Galliumcitrat, Galliumphosphat, Galliumchlorid, Galliumfluorid, Galliumcarbonat, Galliumformiat, Galliumacetat, Galliumsulfat, Galliumtartrat, Galliumoxalat und Galliumoxid ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Mundwasser nach Anspruch 5, wobei besagte Erkrankung oder Störung ausgewählt ist aus der Gruppe bestehend aus Zahnkaries, Plaque, Paradontalerkrankungen, Halitosis und Gingivitis.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Mundwasser nach Anspruch 5 oder Anspruch 6, wobei die Konzentration der Galliumverbindung
<claim-text>i) mindestens etwa 0,1 µM; oder</claim-text>
<claim-text>ii) mindestens etwa 50 µM; oder</claim-text>
<claim-text>iii) mindestens etwa 100 µM<br/>
beträgt.</claim-text></claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Mundwasser nach einem der Ansprüche 5 bis 7, wobei besagtes pathogenes Bakterium mindestens eines ausgewählt aus der Gruppe bestehend aus <i>Streptococcus mutans, Streptococcus sanguis, Streptococcus gordonii, Atopobium parvulum, Porphyromonas gingivalis</i> und <i>Eubacterium sulci</i> ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Galliumverbindung ausgewählt aus der Gruppe bestehend aus Galliumnitrat, Galliummaltolat, Galliumcitrat, Galliumphosphat, Galliumchlorid, Galliumfluorid, Galliumcarbonat, Galliumformiat, Galliumacetat, Galliumsulfat, Galliumtartrat, Galliumoxalat und Galliumoxid zur Verwendung bei der Behandlung von Erkrankungen und Störungen in der Mundhöhle, die mit pathogenen Bakterien in Zusammenhang stehen, durch Kontrolle des Wachstums besagter pathogener Bakterien in der Mundhöhle, wobei die Galliumionenkonzentration am Anwendungsort
<claim-text>i) mindestens etwa 0,1 µM; oder</claim-text>
<claim-text>ii) mindestens etwa 50 µM; oder</claim-text>
<claim-text>iii) mindestens etwa 100 µM</claim-text>
beträgt.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Galliumverbindung nach Anspruch 9, die als eine Zahnpasta oder ein Mundwasser formuliert ist.<!-- EPO <DP n="34"> --></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Galliumverbindung nach Anspruch 9 oder Anspruch 10 zur Verwendung in einem Verfahren zur Kontrolle des Wachstums pathogener Bakterien in der Mundhöhle, <b>dadurch gekennzeichnet, dass</b> eine für die Prophylaxe wirksame Menge der Galliumverbindung auf die Oberfläche eines Zahnes und/oder in der Mundhöhle eines Individuums angewendet wird.</claim-text></claim></claims><claims mxw-id="PCLM56979261" lang="EN" load-source="patent-office"><!-- EPO <DP n="29"> --><claim id="c-en-01-0001" num="0001"><claim-text>A toothpaste comprising a gallium compound in a prophylactically effective amount for use in the treatment of diseases and disorders in the oral cavity associated with pathogenic bacteria by controlling the growth of said pathogenic bacteria in the oral cavity, wherein said compound is at least one selected from the group consisting of gallium nitrate, gallium maltolate; gallium citrate, gallium phosphate, gallium chloride, gallium fluoride, gallium carbonate, gallium formate, gallium acetate, gallium sulfate, gallium tartrate, gallium oxalate, and gallium oxide.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The toothpaste of claim 1, wherein said disease or disorder is selected from the group consisting of dental caries, plaques, periodontal diseases, halitosis, and gingivitis.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The toothpaste of claim 1 or claim 2, wherein the gallium ion concentration at the site of the application is
<claim-text>i) at least about 0,1 µM; or</claim-text>
<claim-text>ii) at least about 50 µM; or</claim-text>
<claim-text>iii) at least about 100 µM.</claim-text></claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The toothpaste of any one of claims 1 to 3, wherein said pathogenic bacterium is at least one selected from the group consisting of <i>Streptococcus mutans, Streptococcus sanguis, Streptococcus gordonii, Atopobium parvulum, Porphyromonas gingivalis, and Eubacterium sulci.</i></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A mouthwash comprising a gallium compound in a prophylactically effective amount for use in the treatment of diseases and disorders in the oral cavity associated with pathogenic bacteria by controlling the growth of said pathogenic bacteria in the oral cavity, wherein said compound is at least one selected from the group consisting of gallium nitrate, gallium maltolate, gallium citrate, gallium phosphate, gallium chloride, gallium fluoride, gallium carbonate, gallium formate, gallium acetate, gallium sulfate, gallium tartrate, gallium oxalate, and gallium oxide.<!-- EPO <DP n="30"> --></claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The mouthwash of claim 5, wherein said disease or disorder is selected from the group consisting of dental caries, plaques, periodontal diseases, halitosis, and gingivitis.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The mouthwash of claim 5 or claim 6, wherein the concentration of the gallium compounds is
<claim-text>i) at least about 0,1 µM; or</claim-text>
<claim-text>ii) at least about 50 µM; or</claim-text>
<claim-text>iii) at least about 100 µM</claim-text></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The mouthwash of any one of claims 5 to 7, wherein said pathogenic bacterium is at least one selected from the group consisting of <i>Streptococcus mutans, Streptococcus sanguis, Streptococcus gordonii, Atopobium parvulum, Porphyromonas gingivalis, and Eubacterium sulci.</i></claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A gallium compound selected from the group consisting of gallium nitrate, gallium maltolate, gallium citrate, gallium phosphate, gallium chloride, gallium fluoride, gallium carbonate, gallium formate, gallium acetate, gallium sulfate, gallium tartrate, gallium oxalate, and gallium oxide for use in the treatment of diseases and disorders in the oral cavity associated with pathogenic bacteria by controlling the growth of said pathogenic bacteria in the oral cavity, wherein the gallium ion concentration at the site of the application is
<claim-text>i) at least about 0,1 µM; or</claim-text>
<claim-text>ii) at least about 50 µM; or</claim-text>
<claim-text>iii) at least about 100 µM.</claim-text></claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The gallium compound of claim 9, which is formulated as a toothpaste or a mouthwash.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The gallium compound of claim 9 or claim 10 for use in a method for controlling growth of pathogenic bacteria in the oral cavity, <b>characterized in that</b><!-- EPO <DP n="31"> --> a prophylactically effective amount of said gallium compound is applied to a tooth surface and/or an oral cavity of a subject.</claim-text></claim></claims><claims mxw-id="PCLM56979262" lang="FR" load-source="patent-office"><!-- EPO <DP n="35"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Pâte dentifrice comprenant un composé de gallium selon une quantité efficace sur le plan prophylactique pour une utilisation dans le traitement de maladies et de troubles de la cavité orale associés à des bactéries pathogènes, par le contrôle de la croissance desdites bactéries pathogènes dans la cavité orale, <b>caractérisé en ce que</b> ledit composé est au moins un composé choisi dans le groupe constitué par le nitrate de gallium, le maltolate de gallium, le citrate de gallium, le phosphate de gallium, le chlorure de gallium, le fluorure de gallium, le carbonate de gallium, le formiate de gallium, l'acétate de gallium, le sulfate de gallium, le tartrate de gallium, l'oxalate de gallium et l'oxyde de gallium.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Pâte dentifrice selon la revendication 1, <b>caractérisée en ce que</b> ladite maladie ou ledit trouble est choisi(e) dans le groupe constitué par les caries dentaires, la plaque dentaire, les maladies parodontales, l'halitose et la gingivite.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Pâte dentifrice selon la revendication 1 ou la revendication 2, <b>caractérisée en ce que</b> la concentration en ions gallium au niveau du site d'application est
<claim-text>i) d'au moins environ 0,1 µM; ou</claim-text>
<claim-text>ii) d'au moins environ 50 µM; ou</claim-text>
<claim-text>iii) d'au moins environ 100 µM.</claim-text></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Pâte dentifrice selon l'une quelconque des revendications à 3, <b>caractérisée en ce que</b> ladite bactérie pathogène est au moins une bactérie choisie dans le groupe constitué par <i>Streptococcus mutans, Streptococcus sanguis, Streptococcus gordonii,Atopobium parvulum, Porphyromonas gingivalis</i> et <i>Eubacterium sulci.</i></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Bain de bouche comprenant un composé de gallium selon une quantité efficace sur le plan prophylactique pour une utilisation dans le traitement de maladies et de troubles de la cavité orale associés à des bactéries pathogènes, par le contrôle de la croissance desdites bactéries<!-- EPO <DP n="36"> --> pathogènes dans la cavité orale, <b>caractérisé en ce que</b> ledit composé est au moins un composé choisi dans le groupe constitué par le nitrate de gallium, le maltolate de gallium, le citrate de gallium, le phosphate de gallium, le chlorure de gallium, le fluorure de gallium, le carbonate de gallium, le formiate de gallium, l'acétate de gallium, le sulfate de gallium, le tartrate de gallium, l'oxalate de gallium et l'oxyde de gallium.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Bain de bouche selon la revendication 5, <b>caractérisé en ce que</b> ladite maladie ou ledit trouble est choisi(e) dans le groupe constitué par les caries dentaires, la plaque dentaire, les maladies parodontales, l'halitose et la gingivite.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Bain de bouche selon la revendication 5 ou la revendication 6, <b>caractérisé en ce que</b> la concentration en composé de gallium est
<claim-text>i) d'au moins environ 0,1 µM; ou</claim-text>
<claim-text>ii) d'au moins environ 50 µM; ou</claim-text>
<claim-text>iii) d'au moins environ 100 µM.</claim-text></claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Bain de bouche selon l'une quelconque des revendications 5 à 7, <b>caractérisé en ce que</b> ladite bactérie pathogène est au moins une bactérie choisie dans le groupe constitué par <i>Streptococcus mutans, Streptococcus sanguis, Streptococcus gordonii, Atopobium parvulum, Porphyromonas gingivalis</i> et <i>Eubacterium sulci.</i></claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Composé de gallium choisi dans le groupe constitué par le nitrate de gallium, le maltolate de gallium, le citrate de gallium, le phosphate de gallium, le chlorure de gallium, le fluorure de gallium, le carbonate de gallium, le formiate de gallium, l'acétate de gallium, le sulfate de gallium, le tartrate de gallium, l'oxalate de gallium et l'oxyde de gallium, pour une utilisation dans le traitement de maladies et de troubles de la cavité orale associés à des bactéries pathogènes, par le contrôle de la croissance desdites bactéries pathogènes dans la cavité orale, <b>caractérisé en ce que</b> la concentration en ions gallium au niveau du site d'application est
<claim-text>i) d'au moins environ 0,1 µM; ou</claim-text>
<claim-text>ii) d'au moins environ 50 µM; ou</claim-text>
<claim-text>iii) d'au moins environ 100 µM.</claim-text></claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Composé de gallium selon la revendication 9, qui est formulé sous forme de pâte dentifrice ou de bain de bouche.<!-- EPO <DP n="37"> --></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Composé de gallium selon la revendication 9 ou la revendication 10, pour une utilisation dans une méthode de contrôle de la croissance de bactéries pathogènes dans la cavité orale, <b>caractérisé en ce qu'</b>une quantité efficace sur le plan prophylactique dudit composé de gallium est appliquée à une surface dentaire et/ou à la cavité orale d'un sujet.</claim-text></claim></claims><drawings mxw-id="PDW16668816" load-source="patent-office"><!-- EPO <DP n="38"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="140" he="233" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
